<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Hardinger, PharmD, BCPS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are three commercially available mammalian (mechanistic) target of rapamycin (mTOR) inhibitors the US Food and Drug Administration (FDA) approved in the United States: <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, and <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>. Sirolimus (rapamycin) is a macrocyclic triene antibiotic that is produced by fermentation of <em>Streptomyces hygroscopicus</em>. Sirolimus was discovered from a soil sample collected in Rapa Nui, which is also known as Easter Island [<a href="#rid1">1</a>]. Although it was originally developed as an antifungal agent, it was later found to have immunosuppressive (US FDA approval in 2003 for prevention of acute rejection in kidney transplantation) and antiproliferative properties that may be useful to treat or prevent proliferative diseases such as tuberous sclerosis, psoriasis, and malignancy. Temsirolimus and everolimus are both analogs of sirolimus approved for the treatment of renal cell carcinoma. Everolimus is US FDA approved for kidney and liver transplant rejection prophylaxis.</p><p>The pharmacology of the mTOR inhibitors and their use and efficacy in kidney transplant recipients will be reviewed here. A discussion of immunosuppressive therapy in kidney transplant recipients is presented separately. (See  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Following entry into the cytoplasm, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> bind to the FK binding protein and presumably modulate the activity of the mTOR [<a href="#rid2">2</a>]. The mTOR inhibits interleukin (IL)-2-mediated signal transduction, resulting in cell-cycle arrest in the G1-S phase [<a href="#rid2">2,3</a>]. Sirolimus and everolimus block the response of T and B cell activation by cytokines, which prevents cell-cycle progression and proliferation; by contrast, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> inhibit the production of cytokines [<a href="#rid4">4</a>].</p><p><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> also appears to inhibit proliferation of smooth muscle cells [<a href="#rid5">5</a>] and, since there is activation of the sirolimus target in tuberous sclerosis lesions, may dampen the growth of angiomyolipomas with tuberous sclerosis [<a href="#rid6">6</a>]. Sirolimus may also have antimalignancy potential [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> received approval for treatment of advanced renal cell carcinoma in 2007 and 2009, respectively. (See  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>.)</p><p class="headingAnchor" id="H2315288727"><span class="h1">FORMULATIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> is available in a 1 mg/mL oral solution (60 mL) and a 0.5, 1, and 2 mg triangular-shaped tablet. Although the oral solution and tablet are not bioequivalent, clinical equivalence has been demonstrated [<a href="#rid3">3</a>].</p><p><a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">Everolimus</a> is available as a 0.25, 0.5, 0.75, and 1 mg round, flat tablet.</p><p class="headingAnchor" id="H2815206205"><span class="h1">DOSE AND ADMINISTRATION</span></p><p class="headingAnchor" id="H1517803146"><span class="h2">Administration</span></p><p class="bulletIndent1"><span class="glyph">●</span>Sirolimus – <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> is typically administered as a tablet, although a solution is available for those who are not able to swallow.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> oral solution should be taken in the following manner:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Empty the medication from the amber syringe into a glass or plastic container.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Then, it should be vigorously stirred with 2 ounces of water or orange juice.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After immediately drinking the mixture, the container should again be filled with 4 ounces of fluid and consumed immediately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> should not be mixed with grapefruit juice.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The oral solution should be protected from light and stored under refrigeration at all times to prevent degradation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Everolimus – <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">Everolimus</a> is administered as a tablet.</p><p></p><p class="headingAnchor" id="H2267500001"><span class="h2">Dose</span><span class="headingEndMark"> — </span>Clinical trials of initial immunosuppressive regimens after kidney transplant have included <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> as a component of a regimen that includes <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and glucocorticoids [<a href="#rid8">8,9</a>]. In these trials, a one-time loading dose of 6 or 15 mg (three times the maintenance dose), followed by a maintenance dose of either 2 or 5 mg/day, was utilized.</p><p>An initial <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> dose of 0.75 mg given orally twice daily is recommended for adult kidney transplant patients in combination with reduced-dose <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid10">10</a>].</p><p>Limited data on <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> dosing are available in the geriatric and pediatric populations [<a href="#rid3">3,11,12</a>].</p><p class="headingAnchor" id="H450600069"><span class="h2">Dose adjustments</span><span class="headingEndMark"> — </span>In clinical practice, dose adjustments for <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are made based upon several factors including concomitant administration of P450 enzyme inducers or inhibitors, hepatic insufficiency, toxicity, and/or infection [<a href="#rid2">2</a>].</p><p>Dose adjustment of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is not required in the presence of kidney function impairment [<a href="#rid3">3</a>]. By contrast, dose reductions of approximately one-third the normal maintenance dose should be used for patients with hepatic impairment.</p><p>In patients with moderate or severe hepatic impairment (Child-Pugh class B and C), the daily dose of <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> needs to be reduced by one-half the recommended initial daily dose [<a href="#rid10">10</a>].</p><p>Close monitoring of mTOR inhibitors with whole-blood concentrations is indicated. (See <a class="local">'Drug monitoring'</a> below.)</p><p class="headingAnchor" id="H199668773"><span class="h2">Drug monitoring</span><span class="headingEndMark"> — </span>An excellent correlation exists between trough whole-blood levels and the area under the time-concentration curve (AUC) for <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid13">13,14</a>]. Routine therapeutic drug monitoring of sirolimus and everolimus blood concentrations is recommended for all patients [<a href="#rid15">15</a>].</p><p>In clinical practice, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> whole-blood concentrations are being measured by both chromatographic and immunoassay methodologies. The recommended time for collection is one hour prior to the next oral dose. Whole-blood samples should be collected in tubes with ethylenediaminetetraacetic acid (EDTA) and protected from light; samples collected in this fashion are stable for 24 hours at room temperature, up to one week at 2 to 8°C, and up to three months at -20°C.</p><p>When <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is used in combination with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, trough whole-blood sirolimus concentrations of 5 to 15 ng/mL were associated with protection from acute rejection episodes and adverse effects. Sirolimus trough concentrations &gt;15 ng/mL have been correlated with hypertriglyceridemia, thrombocytopenia, and leukopenia. Sirolimus concentrations &lt;5 ng/mL were associated with the occurrence of acute rejection in kidney transplant recipients [<a href="#rid16">16</a>].</p><p>When <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is used with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, higher trough concentrations may be necessary. In a clinical trial of kidney transplant recipients, sirolimus trough concentrations were maintained at 30 ng/mL for the first two months posttransplant, then reduced to 15 ng/mL thereafter. Acute rejection episodes were reported in 28 to 41 percent of patients [<a href="#rid17">17,18</a>].</p><p>Routine monitoring of <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> trough concentrations is recommended in all patients, and the concentrations should fall within the 3 to 8 ng/mL target range [<a href="#rid10">10</a>]. Optimally, dose adjustments of everolimus should be based on trough concentrations obtained four or five days after a previous dosing change [<a href="#rid19">19-23</a>].</p><p class="headingAnchor" id="H122511499"><span class="h3">Steady-state concentrations</span><span class="headingEndMark"> — </span>Steady-state concentrations of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> occur five to seven days after initiation of therapy or a change in dose. During clinical trials, mean sirolimus whole-blood trough concentrations (determined by immunoassay) were 9 ng/mL (range, 4.5 to 14 ng/mL) and 17 ng/mL (range, 10 to 28 ng/mL) in the 2 and 5 mg treatment groups, respectively.</p><p>Steady-state concentrations of <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> occur after four to five days in kidney transplant patients receiving 0.75 mg twice daily.</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOKINETICS</span></p><p class="headingAnchor" id="H4"><span class="h2">Absorption</span></p><p class="headingAnchor" id="H5"><span class="h3">Peak concentration</span><span class="headingEndMark"> — </span>The time to peak concentration of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is one to two hours [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Bioavailability</span><span class="headingEndMark"> — </span>The mean bioavailability of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> oral solution is 14 percent. When compared with the oral solution, sirolimus tablets have a 27 percent higher bioavailability [<a href="#rid3">3</a>]. The rate and extent of oral absorption of sirolimus may be reduced in Black patients [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Effects of food</span><span class="headingEndMark"> — </span>The absorption of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are altered by concurrent food intake. In 22 healthy volunteers, for example, the administration of sirolimus and a high-fat breakfast resulted in a 34 percent decrease in the maximum concentration (C<sub>max</sub>), a 3.5-fold increase in the time to C<sub>max</sub>, and a 35 percent increase in the area under the time-concentration curve (AUC) of sirolimus when compared with the fasting state [<a href="#rid3">3,10</a>]. To minimize sirolimus variability caused by food [<a href="#rid3">3</a>], we prefer to have patients take sirolimus at 8 AM, usually one to two hours after food ingestion. Everolimus should be taken consistently with or without food [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Distribution</span><span class="headingEndMark"> — </span>The mean volume of distribution of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is 12 L/kg, with 97 percent of the agent being bound to albumin [<a href="#rid3">3</a>]. The highest concentration of sirolimus is found in red blood cells (95 percent). This is followed by plasma (3 percent), lymphocytes (1 percent), and granulocytes (1 percent); usual blood/plasma ratios are approximately 30 [<a href="#rid4">4,13,14,24,25</a>]. In animal studies, high concentrations have been found in heart, intestines, kidneys, liver, spleen, muscle, lungs, and testes. Tissue/blood ratios have usually been &gt;20 [<a href="#rid4">4</a>].</p><p>For <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, plasma protein binding is approximately 74 percent in healthy subjects and in patients with moderate hepatic impairment. The apparent distribution volume from a single-dose pharmacokinetic study in maintenance kidney transplant patients is 342 to 107 L (range 128 to 589 L) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are extensively metabolized in the liver and are substrates for cytochrome P450 3A4 and P-glycoprotein [<a href="#rid2">2,3,10</a>]. The extent of metabolism of sirolimus in the intestinal wall is unknown [<a href="#rid24">24,26</a>]. Sirolimus is countertransported in the gut lumen by P-glycoprotein. These processes account for low bioavailability and high pharmacokinetic variability [<a href="#rid4">4,24,26</a>].</p><p>Metabolites contribute to &lt;10 percent of immunosuppressive activity of the parent compound, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>. Known metabolites include hydroxy sirolimus, desmethyl sirolimus, and hydroxymethyl sirolimus. <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">Everolimus</a>, the 40-O-(2 hydroxyethyl) derivative of sirolimus, has six predominant metabolites, all with minimal immunosuppressive activity.</p><p class="headingAnchor" id="H10"><span class="h2">Excretion</span><span class="headingEndMark"> — </span>Total body clearance of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is 127 to 240 mL/hour/kg [<a href="#rid4">4,13,14,27</a>]. Large intersubject variability occurs in the oral clearance of sirolimus, which has been reported to be 45 percent higher in Black patients when compared with other patients [<a href="#rid13">13</a>].</p><p><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are mainly excreted in the feces, with a small percent in the urine [<a href="#rid3">3,10</a>]. The elimination half-life of sirolimus is 57 to 63 hours [<a href="#rid4">4,13,24,27</a>], which enables once-daily dosing. Everolimus has a shorter half-life of approximately 30 hours [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H435034967"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Because <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are substrates for cytochrome P450 3A, the coadministration of sirolimus with cytochrome P450 3A inducers (such as some anticonvulsants, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, St. John's wort) and with cytochrome P450 3A inhibitors (such as azole antifungals, nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit) can result in significant interactions. Therapeutic drug monitoring and dose reduction should also be considered when sirolimus or everolimus is coadministered with cannabidiol, which can increase blood levels of these agents [<a href="#rid28">28</a>]. Detail concerning mTOR inhibitor drug interactions and suggestions for their management are described in the tables  (<a class="graphic graphic_table graphicRef110436" href="/d/graphic/110436.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef73326" href="/d/graphic/73326.html" rel="external">table 3</a>). Additional information is available in the <a class="external" href="/drug-interactions">drug interactions program</a> provided by UpToDate.</p><p class="headingAnchor" id="H33010173"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span>Concurrent administration of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> results in significantly higher peak/trough levels and AUC when compared with their administration four hours apart [<a href="#rid29">29</a>]. This was shown in a single-dose drug-interaction study in which sirolimus 10 mg and cyclosporine 300 mg oral soft gelatin capsules were administered either simultaneously or four hours apart [<a href="#rid29">29</a>]. When given together, the sirolimus mean C<sub>max</sub> and AUC were increased by 116 and 230 percent, respectively, relative to administration of sirolimus alone. Whole-blood trough levels increased by approximately 30 percent with concomitant dosing, and the time to peak levels was also shorter (1.8 versus 2.5 hours). By comparison, when sirolimus was given four hours after cyclosporine, the C<sub>max</sub> and AUC were increased by 37 and 80 percent, respectively, compared with administration of sirolimus alone. The mean cyclosporine C<sub>max</sub> and AUC were not significantly affected by sirolimus when given concomitantly or four hours after cyclosporine.</p><p>Because of these drug interactions and additive side effects (hypertriglyceridemia, possibly thrombotic thrombocytopenic purpura-hemolytic uremic syndrome [TTP-HUS]) with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, we prefer <strong>not</strong> to use cyclosporine with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>. Nevertheless, when we do use the combination of cyclosporine and sirolimus, it is usually in the setting of administering sirolimus as either rescue therapy or to help reduce cyclosporine toxicity. In this setting, it is recommended that the time of administration of sirolimus be consistent with that of the administration of cyclosporine (ie, consistently administer sirolimus at the same time as cyclosporine or four hours after the cyclosporine dose) to avoid variability in drug exposure. Serum drug concentrations should be carefully monitored.</p><p>In a single-dose study in healthy subjects, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> administered at a dose of 175 mg increased <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> AUC by 168 percent (range 46 to 365 percent) and C<sub>max</sub> by 82 percent when administered with 2 mg everolimus, compared with administration of everolimus alone [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3103433456"><span class="h3">Tacrolimus</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> have different mechanisms of action, they share the same binding protein (FKBP-12) [<a href="#rid2">2</a>]. Initial in vitro experiments reported an antagonist effect between sirolimus and tacrolimus. However, because of the ubiquitous nature of FKBP-12, in vivo studies of pharmacologic doses of sirolimus did not reveal competitive inhibition [<a href="#rid30">30</a>].</p><p><a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> does not have the same pharmacokinetic interactions with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. In a crossover study, simultaneous and separate (by four hours) administration of sirolimus and tacrolimus were compared. No significant interactions were found in pharmacokinetic parameters, including AUC and C<sub>max</sub> [<a href="#rid31">31</a>].</p><p>A unique form of cast nephropathy has been described in a few patients with delayed allograft function and extensive tubular damage who were being administered <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> plus <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid32">32</a>]. Casts were histologically indistinguishable from those observed with myeloma nephropathy. (See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are associated with a number of possible adverse effects including leukopenia, thrombocytopenia, anemia, hypercholesterolemia, hypertriglyceridemia, diarrhea, and others. Among kidney and pancreas-kidney transplant recipients, an increased mortality risk was associated with sirolimus- compared with non-sirolimus-containing immunosuppressive regimens. (See <a class="local">'Mortality'</a> below.)</p><p class="headingAnchor" id="H1258239613"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Sirolimus-based immunosuppression has been associated with an increased risk of posttransplant mortality when compared with calcineurin inhibitor-based strategies. A systematic review and meta-analysis of 21 randomized trials examined the risk of malignancy and death among 5876 kidney and kidney-pancreas transplant recipients treated with and without <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid33">33</a>]. Patients treated with sirolimus, compared with those without sirolimus, had a lower risk of malignancy (adjusted hazard ratio [HR] 0.60, 95% CI 0.39-0.93) but a higher risk of mortality (HR 1.43, 95% CI 1.21-1.71). The increased mortality among sirolimus-treated patients was driven by an increase in cardiovascular and infection-related deaths.</p><p>In an observational study of 9353 kidney transplant recipients, the use of mTOR inhibitors (either <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>) was associated with a higher risk of all-cause mortality (HR 1.47, 95% CI 1.23-1.76) and death from malignancy (HR 1.37, 95% 1.09-1.71) [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Hematologic effects</span><span class="headingEndMark"> — </span>Anemia, thrombocytopenia, and leukopenia can be observed in those administered <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>In clinical trials, anemia has been reported in 19 to 57 percent of patients, with variability based in part on time posttransplant [<a href="#rid3">3,7,35</a>]. The combination of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> plus <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> may be associated with an enhanced incidence of anemia [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia has been observed in 8 to 30 percent of subjects [<a href="#rid3">3,7</a>]. Reductions in platelet count are dose related and usually occur 9 to 10 days after initiation of treatment [<a href="#rid37">37,38</a>]. Normalization of platelet counts is seen within two weeks of discontinuation [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukopenia, which does not appear to be dose related, is evident within two weeks of initiation of therapy and is reversible upon discontinuation [<a href="#rid37">37,38</a>]. In one study, among 64 patients administered <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> in a randomized trial (target trough concentration of 6 to 12 ng/ml), seven (11 percent) developed leukopenia [<a href="#rid7">7</a>].</p><p></p><p>Similar hematological effects have been reported with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid10">10</a>].</p><p>Anemia associated with mTOR inhibitors is generally mild and reversible. If a patient has anemia posttransplant, bleeding, iron deficiency, and malignancy should also be excluded (see  <a class="medical medical_review" href="/d/html/7330.html" rel="external">"Anemia and the kidney transplant recipient", section on 'Pathogenesis and risk factors'</a>). Leukopenia or thrombocytopenia associated with mTOR inhibitors may occur if the mTOR inhibitor is combined with other medications that cause leukopenia or thrombocytopenia (eg, antithymocyte globulin, <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a>). Close monitoring of concomitant drugs, blood counts, and symptoms and signs (fatigue, pallor, fever, signs of infection, easy bruising, bleeding) is warranted.</p><p class="headingAnchor" id="H21"><span class="h3">Hemolytic uremic syndrome/thrombotic microangiopathy</span><span class="headingEndMark"> — </span>Hemolytic uremic syndrome (HUS)/thrombotic microangiopathy has been reported with the combination of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> immunosuppressive regimen [<a href="#rid39">39-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>HUS was reported in one group of 10 patients administered <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid39">39</a>]. These patients were noted to have higher cyclosporine and sirolimus levels than those without HUS, and discontinuation of these agents resulted in reversal of HUS in most cases. Of note, the incidence of HUS at this center was lower on a regimen of cyclosporine and sirolimus when compared with historic controls on a tacrolimus- or cyclosporine-based regimen without sirolimus [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center cohort study, 13 of 368 patients developed biopsy-proven thrombotic microangiopathy [<a href="#rid40">40</a>]. The incidence was highest with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> (20 percent, six patients), compared with other regimens, including cyclosporine plus <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> plus mycophenolate, and tacrolimus plus sirolimus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, HUS was reported in five lung transplant recipients who received <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid42">42</a>].</p><p></p><p>An increased rate of hepatic artery thrombosis, graft loss, and death has also been reported in liver transplant recipients. In two multicenter, randomized trials in de novo liver transplant recipients, the use of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> in combination with either <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> was associated with an increased rate of hepatic artery thrombosis [<a href="#rid3">3</a>]. Furthermore, in one phase II study, the use of sirolimus and tacrolimus was associated with an increased rate of death and graft loss.</p><p class="headingAnchor" id="H22"><span class="h2">Metabolic effects</span><span class="headingEndMark"> — </span>Hyperlipidemia (23 to 57 percent) and hypercholesterolemia (38 to 46 percent) are dose-related effects of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> therapy that occur via the inhibition of lipoprotein lipase [<a href="#rid7">7,43-45</a>]. Similar effects are seen with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid10">10</a>].</p><p>Hyperlipidemia and hypertriglyceridemia should be assessed before initiating mTOR inhibitor therapy. Patients should have lipid levels checked at baseline and routinely monitored while the patient remains on treatment. Patients taking mTOR inhibitors should be educated on strategies (eg, low-fat diet, exercise) to manage hyperlipidemia or hypertriglyceridemia. Drug management may be necessary.</p><p>Long-term exposure to <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> may also cause deterioration of glucose metabolism and promote new-onset diabetes after transplantation. A discussion of sirolimus and posttransplant diabetes mellitus is presented separately. (See  <a class="medical medical_review" href="/d/html/7327.html" rel="external">"Kidney transplantation in adults: Posttransplantation diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Gastrointestinal system</span><span class="headingEndMark"> — </span>Common gastrointestinal adverse events include constipation (28 to 36 percent), diarrhea (25 to 42 percent), dyspepsia (17 to 25 percent), nausea (25 to 36 percent), and vomiting (19 to 25 percent) [<a href="#rid3">3,7,10</a>].</p><p>Painful mouth ulcers, not related to herpes simplex virus, have been reported in some patients taking <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid10">10</a>]. It is unclear if this adverse effect is dose related. In addition, oral ulcers may occur with the combination of sirolimus and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and may be seen more frequently in glucocorticoid-avoidance protocols [<a href="#rid46">46,47</a>]. In a study cited above, among 64 patients administered sirolimus in a randomized trial (target trough concentration of 6 to 12 ng/mL), 24 (38 percent) developed aphthous ulcers [<a href="#rid7">7</a>].</p><p>Mouth sores may be managed with baking soda rinses and topical anesthetics (viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>) or, in severe cases, dose reduction or discontinuation of the mTOR inhibitor.</p><p><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> may cause or delay healing of gastric or duodenal ulcers [<a href="#rid48">48-51</a>]. (See  <a class="medical medical_review" href="/d/html/23.html" rel="external">"Unusual causes of peptic ulcer disease", section on 'Non-NSAID medications'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Respiratory system</span><span class="headingEndMark"> — </span>Progressive interstitial pneumonitis has been observed in a number of transplant recipients [<a href="#rid3">3,7,52-56</a>], with an incidence of 22 percent in one study [<a href="#rid7">7</a>]. Increased risk factors for pneumonitis include a late switch to <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and impaired kidney function [<a href="#rid55">55</a>]. Clinical symptoms consist of dyspnea, dry cough, fever, and fatigue [<a href="#rid54">54</a>]. In one report of 24 patients, radiographic and bronchoalveolar lavage principally revealed bronchiolitis obliterans organizing pneumonia and lymphocytic alveolitis [<a href="#rid54">54,55</a>]. Complete recovery was observed in all patients within six months of sirolimus withdrawal.</p><p class="headingAnchor" id="H25"><span class="h2">Kidney function</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> nephrotoxicity can manifest in various ways that include acute kidney injury (AKI), proteinuria, prolongation of delayed allograft function, and thrombotic microangiopathy. The combination of sirolimus and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> has caused synergistic nephrotoxicity in animals and humans [<a href="#rid53">53</a>], which may be due to increased renal and whole-blood levels of cyclosporine [<a href="#rid57">57</a>] and/or the resultant increase in the fibrogenic cytokine transforming growth factor (TGF)-beta [<a href="#rid58">58,59</a>]. In addition, sirolimus inhibits P-glycoprotein-mediated efflux of cyclosporine from renal tubular epithelial cells, thereby increasing intratubular levels of cyclosporine and potentiating cyclosporine nephrotoxicity [<a href="#rid60">60</a>].</p><p>During phase III clinical trials that used combination therapy with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, the mean serum creatinine concentration and glomerular filtration rates (GFRs) were increased and decreased, respectively. These effects were not observed with cyclosporine and placebo or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> controls. In addition, the combination of sirolimus plus <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, compared with tacrolimus and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> regimens, is consistently associated with decreased kidney function in several prospective studies [<a href="#rid61">61-64</a>].</p><p>Kidney function and proteinuria should therefore be carefully and routinely monitored in patients treated with combination therapy with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and a calcineurin inhibitor [<a href="#rid3">3</a>].</p><p>There is also some evidence that <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> may be associated with delayed allograft function [<a href="#rid32">32,65,66</a>]. In a study of 144 first deceased- or living-donor kidney allograft recipients, delayed graft function was significantly more common in patients treated with rapamycin than without this agent (25 versus 9 percent) [<a href="#rid32">32</a>]. However, given that these were retrospective, nonrandomized studies, these results may reflect bias that sirolimus may have been administered because of the perception of less nephrotoxicity with this agent. Delayed graft function has not been observed with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid20">20</a>].</p><p>Issues related to kidney function, calcineurin inhibitor withdrawal, and <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> are discussed below. (See <a class="local">'Use in kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H26"><span class="h3">Proteinuria</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> has also been associated with proteinuria and a glomerulonephropathy (particularly focal segmental glomerulosclerosis [FSGS]), most commonly in patients who are converted from a calcineurin inhibitor to sirolimus [<a href="#rid7">7,67-80</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective study of 68 kidney transplant recipients in whom <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> was substituted for a calcineurin inhibitor, proteinuria was assessed prior to and at 3, 6, 12, and 24 months after the substitution [<a href="#rid71">71</a>]. Compared with baseline levels (mean of 0.36 grams/day), proteinuria markedly increased at 3, 6, 12, and 24 months (1.35, 1.67, 1.27, and 1.14 grams/day, respectively). Proteinuria was reversible among the 19 patients in whom sirolimus was withdrawn (1.95 to 0.9 grams/day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study of patients converted to <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, 64 percent developed proteinuria, with 30 percent of these developing FSGS [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A collapsing form of FSGS has been associated with the use of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, which had been used to treat a patient with Kaposi sarcoma [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)"</a>.)</p><p></p><p>Possible mechanisms for proteinuria with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> involve reduced tubular protein reabsorption [<a href="#rid81">81</a>], podocyte dysregulation [<a href="#rid77">77</a>], and overexpression of vascular endothelial growth factor that enhances cell wall permeability, leading to collapsing FSGS [<a href="#rid69">69</a>].</p><p>Conversion to an mTOR inhibitor from a calcineurin inhibitor should only occur in patients with mild proteinuria and an estimated GFR of more than 40 mL/min [<a href="#rid80">80</a>].</p><p>Mild proteinuria may be treated with angiotensin-converting enzyme (ACE) inhibitors, and heavy proteinuria may require drug discontinuation.</p><p class="headingAnchor" id="H27"><span class="h3">Other kidney disorders</span><span class="headingEndMark"> — </span>A unique form of cast nephropathy has been described in a few patients with delayed allograft function and extensive tubular damage who were being administered <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> plus <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid32">32</a>]. Casts were histologically indistinguishable from those observed with myeloma nephropathy.</p><p>AKI occurring in association with myoglobinuria and myoglobulin-appearing casts have also been reported in patients administered <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid82">82</a>]. Additional reports have noted an increased risk of delayed allograft function [<a href="#rid65">65,66</a>]. (See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation"</a> and <a class="local">'Use in kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H28"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Posttransplant lymphoproliferative disease (PTLD) is uncommon among those administered <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. There is also some evidence that sirolimus may actually have antimalignancy effects (see  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>). However, in a retrospective review of Medicare Claims Files data for transplant recipients who underwent transplant from January 2000 to September 2006, de novo use of sirolimus was associated with a 22 percent increased risk of PTLD (hazard ratio [HR] 1.22, 95% CI 1.03-1.45) [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H29"><span class="h2">Teratogenicity/effects on pregnancy and fertility</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are contraindicated in pregnancy, and their use should also be discontinued at least 8 to 12 weeks prior to attempted conception [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/113826.html" rel="external">"Sexual and reproductive health after kidney transplantation", section on 'Management of immunosuppression'</a>.)</p><p>In general, we recommend that women posttransplant who wish to conceive be switched prior to conception from <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> to <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. Upon delivery, it is our general practice to switch the mother back to her basal immunosuppression in view of the potential benefits of the newer agents to prevent late acute rejection and chronic allograft nephropathy.</p><p>There is also some evidence that <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is associated with impaired spermatogenesis. In an observational study of 95 kidney transplant patients, the total sperm count was significantly lower among those who received sirolimus (29 x 10<sup>6</sup> versus 292 x 10<sup>6</sup>) [<a href="#rid85">85</a>]. In addition, patients receiving a sirolimus-based regimen had a significantly decreased fathered-pregnancy rate, compared with those administered a sirolimus-free regimen (5.9 versus 92.9 pregnancies/1000 patient-years). Thus, men who desire to father children should be informed of the risks and benefits associated with exposure to sirolimus.</p><p class="headingAnchor" id="H30"><span class="h2">Other adverse effects</span><span class="headingEndMark"> — </span>In two case reports, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> has been associated with the development of leukocytoclastic vasculitis [<a href="#rid86">86,87</a>]. Sirolimus is also associated with postoperative wound complications. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/7317.html" rel="external">"Kidney transplantation in adults: Nontransplant surgery in the kidney transplant recipient"</a>.)</p><p>There appears to be an increased incidence of angioedema in patients administered ACE inhibitors plus either <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid88">88,89</a>]. This was best shown in a retrospective study of 309 patients administered either sirolimus (144) or everolimus (165), with 137 also being treated with ACE inhibitors [<a href="#rid89">89</a>]. Combined therapy was associated with a 6.6 percent incidence of angioedema, compared with a 1 to 2 percent incidence in those not being administered the combined regimen.</p><p>A large number of cutaneous adverse events can be observed with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid90">90,91</a>]. In one study from France, skin disorders were reported in 79 of 80 kidney transplant patients [<a href="#rid90">90</a>]; the most frequent were acne-like eruptions (46 percent), scalp folliculitis (26 percent), hidradenitis suppurativa (12 percent), edema (55 percent), angioedema (15 percent), aphthous ulceration (60 percent), and epistaxis (60 percent). The peripheral edema associated with mTOR inhibitors may be asymmetric and in some cases may not resolve after discontinuation of the agent.</p><p>Pericardial effusion has been noted with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>. Although most have been reported in cardiac transplant recipients, cases of pericardial effusion were observed in kidney transplant patients given sirolimus [<a href="#rid92">92</a>].</p><p>To date, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> has not been compared with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> in a head-to-head trial, but, in noncomparative trials, the side effects are similar. In trials comparing <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> to everolimus in conjunction with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, the most common adverse reactions observed in the everolimus group were peripheral edema, constipation, hypertension, nausea, anemia, urinary tract infection (UTI), and hyperlipidemia [<a href="#rid20">20-23</a>].</p><p class="headingAnchor" id="H1802441899"><span class="h1">USE IN KIDNEY TRANSPLANTATION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> have been utilized in a number of settings in kidney transplantation, although their use has been decreasing due to the various problems outlined above.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – The efficacy of mTOR inhibitors for primary maintenance immunosuppressive therapy in kidney transplant recipients is well documented. However, early posttransplantation complications of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, particularly delayed allograft function, poor wound healing, adverse short-term outcomes, and an increased incidence of lymphoceles, have limited the de novo use of mTOR inhibitors at some centers. (See <a class="local">'Adverse effects'</a> above and  <a class="medical medical_review" href="/d/html/7317.html" rel="external">"Kidney transplantation in adults: Nontransplant surgery in the kidney transplant recipient"</a> and  <a class="medical medical_review" href="/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression", section on 'Calcineurin inhibitor (CNI)-related toxicity'</a> and  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Calcineurin inhibitor-related toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid withdrawal</strong> – In an attempt to minimize glucocorticoid-induced morbidity, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> has been administered to kidney transplant recipients in whom glucocorticoids were eventually withdrawn [<a href="#rid61">61,93-98</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney allograft nephropathy</strong> – A discussion of the use of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> in patients with chronic kidney allograft nephropathy is discussed separately. (See  <a class="medical medical_review" href="/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory kidney transplant rejection</strong> – The efficacy of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> for refractory kidney allograft rejection has been evaluated in limited preliminary studies [<a href="#rid99">99</a>]. Further study is required to better understand the role of sirolimus in this setting. (See  <a class="medical medical_review" href="/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at risk for cytomegalovirus (CMV) infection</strong> – A lower incidence and severity of CMV infection in transplant recipients treated with mTOR inhibitors has been observed in several clinical trials and meta-analyses [<a href="#rid100">100-102</a>]. Future trials designed to test the effect of mTOR inhibitors on CMV infection should be conducted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with skin cancer</strong> – <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> may have an antineoplastic effect among kidney transplant recipients with squamous cell carcinoma. In one trial, kidney transplant recipients with at least one cutaneous squamous cell carcinoma were randomly assigned to receive sirolimus as a substitute for calcineurin inhibitors or to maintain calcineurin inhibitor therapy [<a href="#rid7">7</a>]. Patients who were converted to sirolimus, compared with those maintained on calcineurin inhibitors, had a lower rate of new squamous cell carcinomas (22 versus 39 percent). More adverse events occurred in the sirolimus group, resulting in discontinuation of sirolimus in 23 percent of patients.</p><p></p><p class="bulletIndent1">Several meta-analyses comparing outcomes in kidney transplant recipients treated with or without <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> have demonstrated lower rates of nonmelanoma skin cancer among patients treated with sirolimus [<a href="#rid33">33,103,104</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> has also been used for the treatment of Kaposi sarcoma after kidney transplantation [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation", section on 'Immunosuppression'</a>.)</p><p></p><p class="headingAnchor" id="H1802439392"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– There are two commercially available mammalian (mechanistic) target of rapamycin (mTOR) inhibitors that are US Food and Drug Administration (FDA) approved in the United States for kidney transplantation, including <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>. Both have immunosuppressive and antiproliferative properties. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action </strong>– <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> block the response of T and B cell activation by cytokines, which prevents cell-cycle progression and proliferation; by contrast, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> inhibit the production of cytokines. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration </strong>– <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are extensively metabolized in the liver and are substrates for cytochrome P450 3A4 and P-glycoprotein. Dose adjustment of sirolimus is not required in the presence of kidney function impairment but is for patients with hepatic impairment. Routine therapeutic drug monitoring of sirolimus blood concentrations is recommended for all patients. The recommended time for collection is one hour prior to the next oral dose. (See <a class="local">'Dose adjustments'</a> above and <a class="local">'Drug monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions </strong>– Because <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are substrates for cytochrome P450 3A, the coadministration of sirolimus with cytochrome P450 3A inducers (such as some anticonvulsants, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, St. John's wort) and with cytochrome P450 3A inhibitors (such as azole antifungals, nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit) can result in significant interactions. (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are associated with a number of possible adverse effects, including leukopenia, thrombocytopenia, anemia, hypercholesterolemia, hypertriglyceridemia, diarrhea, new-onset diabetes, and others. Among kidney transplant recipients, increased mortality risk has been associated with sirolimus compared with non-sirolimus-containing immunosuppressive regimens. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects on pregnancy </strong>– <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are contraindicated in pregnancy. (See <a class="local">'Teratogenicity/effects on pregnancy and fertility'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28:727.</a></li><li><a class="nounderline abstract_t">Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 2004; 24:1159.</a></li><li class="breakAll">Product Information: Rapamune (sirolimus) Oral Solution and Tablets. Philadelphia, PA: Wyeth Laboratories, Division of Wyeth-Ayerst Pharmaceuticals Inc; April 2017.</li><li><a class="nounderline abstract_t">Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17:1148.</a></li><li><a class="nounderline abstract_t">Cao W, Mohacsi P, Shorthouse R, et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59:390.</a></li><li><a class="nounderline abstract_t">El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003; 361:1348.</a></li><li><a class="nounderline abstract_t">Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329.</a></li><li><a class="nounderline abstract_t">Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194.</a></li><li><a class="nounderline abstract_t">MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271.</a></li><li class="breakAll">Product Information: Zortress (everolimus) Tablets. East Hanover, NJ: Novartis Pharmaceutical Corporation; January 2018.</li><li><a class="nounderline abstract_t">Pape L, Ahlenstiel T. mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol 2014; 29:1119.</a></li><li><a class="nounderline abstract_t">David-Neto E, Agena F, Ramos F, et al. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. Transplantation 2017; 101:2133.</a></li><li><a class="nounderline abstract_t">Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37:405.</a></li><li><a class="nounderline abstract_t">Kahan BD, Napoli KL. Role of therapeutic drug monitoring of rapamycin. Transplant Proc 1998; 30:2189.</a></li><li><a class="nounderline abstract_t">Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43:83.</a></li><li><a class="nounderline abstract_t">Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14:97.</a></li><li><a class="nounderline abstract_t">Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036.</a></li><li><a class="nounderline abstract_t">Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.</a></li><li><a class="nounderline abstract_t">Chan L, Hartmann E, Cibrik D, et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010; 90:31.</a></li><li><a class="nounderline abstract_t">Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23:1084.</a></li><li><a class="nounderline abstract_t">Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10:1401.</a></li><li><a class="nounderline abstract_t">Vítko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5:2521.</a></li><li><a class="nounderline abstract_t">Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78:1532.</a></li><li><a class="nounderline abstract_t">Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997; 61:416.</a></li><li><a class="nounderline abstract_t">Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993; 56:1202.</a></li><li><a class="nounderline abstract_t">Briffa N, Morris RE. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997; 10:2630.</a></li><li><a class="nounderline abstract_t">Yatscoff RW, Wang P, Chan K, et al. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17:666.</a></li><li class="breakAll">RAPAMUNE (sirolimus) oral solution. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070,021110s087s088lbl.pdf (Accessed on August 26, 2022).</li><li><a class="nounderline abstract_t">Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63:48.</a></li><li><a class="nounderline abstract_t">Chen H, Qi S, Xu D, et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant Proc 1998; 30:1039.</a></li><li><a class="nounderline abstract_t">McAlister VC, Mahalati K, Peltekian KM, et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24:346.</a></li><li><a class="nounderline abstract_t">Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14:1037.</a></li><li><a class="nounderline abstract_t">Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014; 349:g6679.</a></li><li><a class="nounderline abstract_t">Badve SV, Pascoe EM, Burke M, et al. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. Clin J Am Soc Nephrol 2016; 11:1845.</a></li><li><a class="nounderline abstract_t">Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4:2001.</a></li><li><a class="nounderline abstract_t">Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6:1991.</a></li><li><a class="nounderline abstract_t">Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49:209.</a></li><li><a class="nounderline abstract_t">Groth CG, Brattström C, Claesson K, Bäckman L. New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation. Transplant Proc 1998; 30:4064.</a></li><li><a class="nounderline abstract_t">Langer RM, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine a sirolimus combination. Transplant Proc 2001; 33:3236.</a></li><li><a class="nounderline abstract_t">Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004; 4:946.</a></li><li><a class="nounderline abstract_t">Crew RJ, Radhakrishnan J, Cohen DJ, et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 2005; 20:203.</a></li><li><a class="nounderline abstract_t">Lovric S, Kielstein JT, Kayser D, et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. Nephrol Dial Transplant 2011; 26:3032.</a></li><li><a class="nounderline abstract_t">Kraemer FB, Takeda D, Natu V, Sztalryd C. Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. Metabolism 1998; 47:555.</a></li><li><a class="nounderline abstract_t">Brattström C, Wilczek HE, Tydén G, et al. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998; 30:3950.</a></li><li><a class="nounderline abstract_t">Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384.</a></li><li><a class="nounderline abstract_t">van Gelder T, ter Meulen CG, Hené R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75:788.</a></li><li><a class="nounderline abstract_t">Smith MP, Newstead CG, Ahmad N, et al. Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation. Transplantation 2008; 85:636.</a></li><li><a class="nounderline abstract_t">Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant 2005; 19:250.</a></li><li><a class="nounderline abstract_t">Altomare JF, Smith RE, Potdar S, Mitchell SH. Delayed gastric ulcer healing associated with sirolimus. Transplantation 2006; 82:437.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005; 18:643.</a></li><li><a class="nounderline abstract_t">Molinari M, Al-Saif F, Ryan EA, et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 2005; 5:2799.</a></li><li><a class="nounderline abstract_t">Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343:225.</a></li><li><a class="nounderline abstract_t">Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77:1215.</a></li><li><a class="nounderline abstract_t">Champion L, Stern M, Israël-Biet D, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144:505.</a></li><li><a class="nounderline abstract_t">Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature. Nephrol Dial Transplant 2007; 22:3631.</a></li><li><a class="nounderline abstract_t">Velioglu A, Eryuksel E, Cimsit C, et al. Late Pulmonary Toxicity Associated With Everolimus in a Renal Transplant Patient and Review of the Literature. Exp Clin Transplant 2018; 16:491.</a></li><li><a class="nounderline abstract_t">Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62:311.</a></li><li><a class="nounderline abstract_t">Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65:1262.</a></li><li><a class="nounderline abstract_t">Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75:772.</a></li><li><a class="nounderline abstract_t">Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70:1019.</a></li><li><a class="nounderline abstract_t">Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006; 6:1617.</a></li><li><a class="nounderline abstract_t">Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80:303.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.</a></li><li><a class="nounderline abstract_t">Kaplan B, Kirk AD. Tacrolimus and sirolimus: when bad things happen to good drugs. Am J Transplant 2006; 6:1501.</a></li><li><a class="nounderline abstract_t">McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3:416.</a></li><li><a class="nounderline abstract_t">Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15:228.</a></li><li><a class="nounderline abstract_t">Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17:215.</a></li><li><a class="nounderline abstract_t">Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78:1362.</a></li><li><a class="nounderline abstract_t">Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353:2088.</a></li><li><a class="nounderline abstract_t">Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5:2318.</a></li><li><a class="nounderline abstract_t">Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80:1198.</a></li><li><a class="nounderline abstract_t">Sennesael JJ, Bosmans JL, Bogers JP, et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80:1578.</a></li><li><a class="nounderline abstract_t">Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35:52S.</a></li><li><a class="nounderline abstract_t">Horita Y, Miyazaki M, Koji T, et al. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant 1998; 13:2519.</a></li><li><a class="nounderline abstract_t">Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.</a></li><li><a class="nounderline abstract_t">Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82:368.</a></li><li><a class="nounderline abstract_t">Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2:326.</a></li><li><a class="nounderline abstract_t">Diekmann F, Gutiérrez-Dalmau A, López S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 2007; 22:2316.</a></li><li><a class="nounderline abstract_t">Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8:854.</a></li><li><a class="nounderline abstract_t">Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233.</a></li><li><a class="nounderline abstract_t">Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006; 6:429.</a></li><li><a class="nounderline abstract_t">Pelletier R, Nadasdy T, Nadasdy G, et al. Acute renal failure following kidney transplantation associated with myoglobinuria in patients treated with rapamycin. Transplantation 2006; 82:645.</a></li><li><a class="nounderline abstract_t">Nee R, Hurst FP, Dharnidharka VR, et al. Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011; 92:190.</a></li><li><a class="nounderline abstract_t">EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 Suppl 4:50.</a></li><li><a class="nounderline abstract_t">Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008; 8:1471.</a></li><li><a class="nounderline abstract_t">Hardinger KL, Cornelius LA, Trulock EP 3rd, Brennan DC. Sirolimus-induced leukocytoclastic vasculitis. Transplantation 2002; 74:739.</a></li><li><a class="nounderline abstract_t">Pasqualotto AC, Bianco PD, Sukiennik TC, et al. Sirolimus-induced leukocytoclastic vasculitis: the second case reported. Am J Transplant 2004; 4:1549.</a></li><li><a class="nounderline abstract_t">Stallone G, Infante B, Di Paolo S, et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004; 19:2906.</a></li><li><a class="nounderline abstract_t">Duerr M, Glander P, Diekmann F, et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5:703.</a></li><li><a class="nounderline abstract_t">Mahé E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79:476.</a></li><li><a class="nounderline abstract_t">Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. Br J Dermatol 2009; 160:1322.</a></li><li><a class="nounderline abstract_t">Steele GH, Adamkovic AB, Demopoulos LA, et al. Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database. Transplantation 2008; 85:645.</a></li><li><a class="nounderline abstract_t">Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5:157.</a></li><li><a class="nounderline abstract_t">Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4:980.</a></li><li><a class="nounderline abstract_t">Anil Kumar MS, Moritz MJ, Saaed MI, et al. Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5:1976.</a></li><li><a class="nounderline abstract_t">Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. Am J Transplant 2005; 5:1529.</a></li><li><a class="nounderline abstract_t">Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80:807.</a></li><li><a class="nounderline abstract_t">Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006; 81:832.</a></li><li><a class="nounderline abstract_t">Hong JC, Kahan BD. Sirolimus rescue therapy for refractory rejection in renal transplantation. Transplantation 2001; 71:1579.</a></li><li><a class="nounderline abstract_t">Ghassemieh B, Ahya VN, Baz MA, et al. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant 2013; 32:701.</a></li><li><a class="nounderline abstract_t">Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis. Transplantation 2012; 94:1208.</a></li><li><a class="nounderline abstract_t">Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93:1075.</a></li><li><a class="nounderline abstract_t">Lim WH, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant 2014; 14:2106.</a></li><li><a class="nounderline abstract_t">Yanik EL, Siddiqui K, Engels EA. Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med 2015; 4:1448.</a></li><li><a class="nounderline abstract_t">Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.</a></li></ol></div><div id="topicVersionRevision">Topic 7329 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1102509" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15460177" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current and future immunosuppressive strategies in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15460177" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current and future immunosuppressive strategies in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399599" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sirolimus, a new, potent immunosuppressive agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7532879" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711473" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22830463" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sirolimus and secondary skin-cancer prevention in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963197" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213073" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213073" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740036" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : mTOR inhibitors in pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27798513" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156373" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9723436" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Role of therapeutic drug monitoring of rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14748618" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical pharmacokinetics of everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770413" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221490" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798738" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20517177" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500493" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20455882" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162203" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599319" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129559" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Population pharmacokinetics of sirolimus in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8249123" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Blood distribution of rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426106" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : New immunosuppressive regimens in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8588238" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8588238" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9465841" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9636419" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021624" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660339" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422259" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27445164" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15575902" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16930395" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mycophenolate mofetil and sirolimus combination in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8770969" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865296" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750387" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine a sirolimus combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15147429" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15632351" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310739" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591746" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865258" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hypertriglyceridemia in renal transplant recipients treated with sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18510633" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660502" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347544" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740563" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906046" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Delayed gastric ulcer healing associated with sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15910287" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Gastrointestinal complications in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16212644" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928875" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114088" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sirolimus-associated pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585664" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611248" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001620" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Late Pulmonary Toxicity Associated With Everolimus in a Renal Transplant Patient and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8779675" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086465" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660500" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837925" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827862" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16082323" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686761" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827845" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Tacrolimus and sirolimus: when bad things happen to good drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694063" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694177" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15112032" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548976" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282189" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Post-transplantation proteinuria and sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095517" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314786" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Proteinuria following a switch from calcineurin inhibitors to sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371929" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Conversion from cyclosporine to sirolimus in stable renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742467" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9794554" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594796" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906035" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699432" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : High sirolimus levels may induce focal segmental glomerulosclerosis de novo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452413" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261172" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155978" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426332" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969287" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Acute renal failure following kidney transplantation associated with myoglobinuria in patients treated with rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21577180" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091650" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18510638" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sirolimus may reduce fertility in male renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352895" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sirolimus-induced leukocytoclastic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307846" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sirolimus-induced leukocytoclastic vasculitis: the second case reported.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496567" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093343" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729175" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302070" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347546" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636625" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15147433" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996248" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888064" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210969" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570004" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435968" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sirolimus rescue therapy for refractory rejection in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664526" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269449" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683823" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088685" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26108799" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800227" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Sirolimus for Kaposi's sarcoma in renal-transplant recipients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
